Senior Director, Global Regulatory Affairs
GlaxoSmithKline - ENTERPRISE
Erin Oliver is currently Senior Director and Regulatory Lead for Rx to OTC Switch for GlaxoSmithKline Consumer Healthcare with responsibility for identifying, evaluating and progressing switch opportunities.
Erin has contributed to or led several Rx to OTC switch programs, including Voltaren Arthritis Pain Gel, Flonase® Allergy Relief and the first-in-class switch of orlistat (alli® capsules). She has presented at various symposia on topics relevant to consumer healthcare including Rx to OTC switch, OTC labeling development, and the role of technology in promoting self-care.
Prior to this role, as Head of US Regulatory Affairs for GSKCH, Erin led a team of regulatory professionals managing all regulatory aspects of a US portfolio - developing and driving regulatory strategies to maximize business opportunities. With 20+ years in the pharmaceutical industry, she has broad-based experience in the development and regulation of Rx and OTC drugs, medical devices, dietary supplements and cosmetics across a wide range of therapeutic categories.
Erin holds a B.S. degree in Biology and M.S. degree in Pharmaceutics from Rutgers University as well as an MBA from Cornell University. Erin is a certified regulatory professional and a fellow of the Regulatory Affairs Professional Society. She’s served as adjunct faculty at Fairleigh Dickinson University School of Pharmacy teaching in the area of regulatory affairs and compliance.
Monday, September 14, 2020
2:05 PM – 3:00 PM EDT